{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:21:38Z","timestamp":1789521698526,"version":"build-2803163510"},"reference-count":197,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.2215\/cjn.01360210","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T23:45:03Z","timestamp":1274744703000},"page":"1312-1329","source":"Crossref","is-referenced-by-count":93,"title":["Prospects for mTOR Inhibitor Use in Patients with Polycystic Kidney Disease and Hamartomatous Diseases"],"prefix":"10.2215","volume":"5","author":[{"given":"Vicente E.","family":"Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Gattone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren P.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weimbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf P.","family":"W\u00fcthrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20230601","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R2-23-20230601","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"R5-23-20230601","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.biochem.75.103004.142819","article-title":"TRP channels","volume":"76","author":"Venkatachalam","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"R6-23-20230601","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibs.2003.11.007","article-title":"TSC2: Filling the GAP in the mTOR signaling pathway","volume":"29","author":"Li","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"R7-23-20230601","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1294-328","article-title":"Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease\u2014A contiguous gene syndrome","volume":"8","author":"Brook-Carter","year":"1994","journal-title":"Nat Genet"},{"key":"R8-23-20230601","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: The last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"R9-23-20230601","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"R10-23-20230601","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: A molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"R11-23-20230601","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"R12-23-20230601","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"R13-23-20230601","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"R14-23-20230601","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the Rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"R15-23-20230601","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ncb996","article-title":"Rheb promotes cell growth as a component of the insulin\/TOR signaling network","volume":"5","author":"Saucedo","year":"2003","journal-title":"Nat Cell Biol"},{"key":"R16-23-20230601","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nature05528","article-title":"Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase","volume":"445","author":"Hsu","year":"2007","journal-title":"Nature"},{"key":"R17-23-20230601","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"R18-23-20230601","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1073\/pnas.0409143102","article-title":"Quantitative phosphorylation profiling of the ERK\/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors","volume":"102","author":"Ballif","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-23-20230601","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol Cell"},{"key":"R20-23-20230601","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-23-20230601","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"key":"R22-23-20230601","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"R23-23-20230601","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth","volume":"126","author":"Inoki","year":"2006","journal-title":"Cell"},{"key":"R24-23-20230601","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev"},{"key":"R25-23-20230601","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1002\/j.1460-2075.1995.tb00212.x","article-title":"The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain","volume":"14","author":"Pearson","year":"1995","journal-title":"EMBO J"},{"key":"R26-23-20230601","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"R27-23-20230601","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","article-title":"Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies","volume":"14","author":"Shah","year":"2004","journal-title":"Curr Biol"},{"key":"R28-23-20230601","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1128\/MCB.01254-05","article-title":"Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis","volume":"26","author":"Shah","year":"2006","journal-title":"Mol Cell Biol"},{"key":"R29-23-20230601","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1101\/gad.1314605","article-title":"Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2","volume":"19","author":"Manning","year":"2005","journal-title":"Genes Dev"},{"key":"R30-23-20230601","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"R31-23-20230601","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R32-23-20230601","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R33-23-20230601","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res"},{"key":"R34-23-20230601","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-3-39","article-title":"Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin","volume":"3","author":"Molhoek","year":"2005","journal-title":"J Transl Med"},{"key":"R35-23-20230601","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet"},{"key":"R36-23-20230601","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.mrrev.2008.06.001","article-title":"The mTOR pathway and its role in human genetic diseases","volume":"659","author":"Rosner","year":"2008","journal-title":"Mutat Res"},{"key":"R37-23-20230601","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/hmg\/ddn192","article-title":"Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 components Rictor and sin1","volume":"17","author":"Rosner","year":"2008","journal-title":"Hum Mol Genet"},{"key":"R38-23-20230601","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/hmg\/ddn325","article-title":"The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway","volume":"18","author":"Hartman","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R39-23-20230601","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"R40-23-20230601","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","article-title":"Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways","volume":"14","author":"Kwiatkowski","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R41-23-20230601","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/humu.10257","article-title":"PTEN: One gene, many syndromes","volume":"22","author":"Eng","year":"2003","journal-title":"Hum Mutat"},{"key":"R42-23-20230601","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jmg.2007.049981","article-title":"Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: Results of a clinical study of PTEN mutation carriers","volume":"44","author":"Lachlan","year":"2007","journal-title":"J Med Genet"},{"key":"R43-23-20230601","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.pathol.2.010506.091940","article-title":"Neurofibromatosis","volume":"2","author":"McClatchey","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"R44-23-20230601","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1101\/gad.1199104","article-title":"Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz\u2013Jeghers syndrome","volume":"18","author":"Corradetti","year":"2004","journal-title":"Genes Dev"},{"key":"R45-23-20230601","doi-asserted-by":"crossref","first-page":"15552","DOI":"10.1073\/pnas.0603781103","article-title":"Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling","volume":"103","author":"Baba","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-23-20230601","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/djm288","article-title":"Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys","volume":"100","author":"Baba","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R47-23-20230601","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R48-23-20230601","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"R49-23-20230601","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1\u20132 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J Cell Biol"},{"key":"R51-23-20230601","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/geno.1996.0596","article-title":"The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome","volume":"38","author":"Sandford","year":"1996","journal-title":"Genomics"},{"key":"R52-23-20230601","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/hmg\/ddp149","article-title":"Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis","volume":"18","author":"Bonnet","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R53-23-20230601","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ndt\/gfn744","article-title":"Activation of the AKT\/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)","volume":"24","author":"Fischer","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R54-23-20230601","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/jmg.33.6.480","article-title":"A cross sectional study of renal involvement in tuberous sclerosis","volume":"33","author":"Cook","year":"1996","journal-title":"J Med Genet"},{"key":"R55-23-20230601","doi-asserted-by":"crossref","first-page":"F1423","DOI":"10.1152\/ajprenal.00275.2007","article-title":"Polycystic kidney disease and renal injury repair: Common pathways, fluid flow, and the function of polycystin-1","volume":"293","author":"Weimbs","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R56-23-20230601","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.4161\/cc.5.21.3408","article-title":"Regulation of mTOR by polycystin-1: Is polycystic kidney disease a case of futile repair?","volume":"5","author":"Weimbs","year":"2006","journal-title":"Cell Cycle"},{"key":"R57-23-20230601","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R58-23-20230601","first-page":"3469","article-title":"Tuberous sclerosis-associated neoplasms express activated p42\/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth","volume":"9","author":"Govindarajan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R59-23-20230601","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"R60-23-20230601","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1681\/ASN.2005060645","article-title":"Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells","volume":"17","author":"Yamaguchi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R61-23-20230601","doi-asserted-by":"crossref","first-page":"27354","DOI":"10.1016\/S0021-9258(19)61518-8","article-title":"Negative regulation of the serine\/threonine kinase B-Raf by Akt","volume":"275","author":"Guan","year":"2000","journal-title":"J Biol Chem"},{"key":"R62-23-20230601","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1440-1797.2007.00811.x","article-title":"Mitotic activation of Akt signaling pathway in Han:SPRD rats with polycystic kidney disease","volume":"12","author":"Wahl","year":"2007","journal-title":"Nephrology (Carlton"},{"key":"R63-23-20230601","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199203000-00002","article-title":"The effect of rapamycin on kidney function in the Sprague\u2013Dawley rat","volume":"53","author":"DiJoseph","year":"1992","journal-title":"Transplantation"},{"key":"R64-23-20230601","doi-asserted-by":"crossref","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","article-title":"Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells","volume":"281","author":"Lieberthal","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"R65-23-20230601","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1681\/ASN.2004030180","article-title":"Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.","volume":"16","author":"Bonegio","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R66-23-20230601","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1681\/ASN.2004100894","article-title":"Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy","volume":"16","author":"Chen","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R67-23-20230601","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/sj.ki.5000161","article-title":"Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis.","volume":"69","author":"Wu","year":"2006","journal-title":"Kidney Int"},{"key":"R68-23-20230601","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1681\/ASN.2005060601","article-title":"Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (Cy\/+) rat","volume":"16","author":"Brown","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R69-23-20230601","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R70-23-20230601","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R71-23-20230601","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4067\/S0716-97602009000400005","article-title":"Mycophenolate mofetil versus rapamycin in Han:SPRD rats with polycystic kidney disease","volume":"42","author":"Zhang","year":"2009","journal-title":"Biol Res"},{"key":"R72-23-20230601","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"R73-23-20230601","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/ndt\/gfp129","article-title":"Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)","volume":"24","author":"Zafar","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R74-23-20230601","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1046\/j.1523-1755.2003.00863.x","article-title":"Delayed cystogenesis and increased ciliogenesis associated with the re-expression of polaris in Tg737 mutant mice","volume":"63","author":"Brown","year":"2003","journal-title":"Kidney Int"},{"key":"R75-23-20230601","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng1216","article-title":"Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis","volume":"34","author":"Olbrich","year":"2003","journal-title":"Nat Genet"},{"key":"R76-23-20230601","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ki.2009.147","article-title":"Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis","volume":"76","author":"Gattone","year":"2009","journal-title":"Kidney Int"},{"key":"R77-23-20230601","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10334-008-0158-7","article-title":"Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD","volume":"22","author":"Reichardt","year":"2009","journal-title":"MAGMA"},{"key":"R78-23-20230601","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub\u00e9 syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"key":"R79-23-20230601","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gene.2008.02.022","article-title":"Identification and characterization of a novel folliculin-interacting protein FNIP2","volume":"415","author":"Hasumi","year":"2008","journal-title":"Gene"},{"key":"R80-23-20230601","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R81-23-20230601","first-page":"1","article-title":"Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice","volume":"51","author":"Spirli","year":"2009","journal-title":"Hepatology"},{"key":"R82-23-20230601","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"R83-23-20230601","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R84-23-20230601","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/01.tp.0000282866.92367.99","article-title":"The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat","volume":"84","author":"Vogelbacher","year":"2007","journal-title":"Transplantation"},{"key":"R85-23-20230601","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2005.12.012","article-title":"Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice","volume":"340","author":"Sakaguchi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"R86-23-20230601","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0041-1345(00)02141-2","article-title":"Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury","volume":"33","author":"Jain","year":"2001","journal-title":"Transplant Proc"},{"key":"R87-23-20230601","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/j.1523-1755.2005.00662.x","article-title":"Inflammation and caspase activation in long-term renal ischemia\/reperfusion injury and immunosuppression in rats.","volume":"68","author":"Yang","year":"2005","journal-title":"Kidney Int"},{"key":"R88-23-20230601","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/01.tp.0000209412.77312.69","article-title":"Apoptosis and caspase-3 in long-term renal ischemia\/reperfusion injury in rats and divergent effects of immunosuppressants","volume":"81","author":"Yang","year":"2006","journal-title":"Transplantation"},{"key":"R89-23-20230601","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.transproceed.2007.01.031","article-title":"The effects of rapamycin in the progression of renal fibrosis","volume":"39","author":"Damiao","year":"2007","journal-title":"Transplant Proc"},{"key":"R90-23-20230601","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2353\/ajpath.2007.060497","article-title":"Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin","volume":"170","author":"Schaefer","year":"2007","journal-title":"Am J Pathol"},{"key":"R91-23-20230601","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1681\/ASN.2005050549","article-title":"Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats","volume":"17","author":"Lloberas","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R92-23-20230601","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/TP.0b013e3181a192bd","article-title":"Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat","volume":"87","author":"Wittmann","year":"2009","journal-title":"Transplantation"},{"key":"R93-23-20230601","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000106782","article-title":"Rapamycin prevents early steps of the development of diabetic nephropathy in rats","volume":"27","author":"Yang","year":"2007","journal-title":"Am J Nephrol"},{"key":"R94-23-20230601","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3181\/0801-RM-29","article-title":"Renal activity of Akt kinase in obese Zucker rats","volume":"233","author":"Zdychova","year":"2008","journal-title":"Exp Biol Med (Maywood"},{"key":"R95-23-20230601","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2353\/ajpath.2007.070412","article-title":"Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin","volume":"171","author":"Sataranatarajan","year":"2007","journal-title":"Am J Pathol"},{"key":"R96-23-20230601","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/j.1523-1755.2005.00732.x","article-title":"Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy","volume":"68","author":"Coombes","year":"2005","journal-title":"Kidney Int"},{"key":"R97-23-20230601","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cellsig.2007.10.027","article-title":"Raptor-Rictor axis in TGF\u03b2-induced protein synthesis","volume":"20","author":"Das","year":"2008","journal-title":"Cell Signal"},{"key":"R98-23-20230601","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.transproceed.2007.01.027","article-title":"The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury","volume":"39","author":"Goncalves","year":"2007","journal-title":"Transplant Proc"},{"key":"R99-23-20230601","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1432-2277.2006.00361.x","article-title":"Effect of rapamycin on renal ischemia-reperfusion injury in mice","volume":"19","author":"Lui","year":"2006","journal-title":"Transpl Int"},{"key":"R100-23-20230601","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/01.TP.0000095897.38634.30","article-title":"Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury","volume":"76","author":"Fuller","year":"2003","journal-title":"Transplantation"},{"key":"R101-23-20230601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000225772.22757.5e","article-title":"Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance","volume":"82","author":"Lieberthal","year":"2006","journal-title":"Transplantation"},{"key":"R102-23-20230601","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/ndt\/gfm191","article-title":"Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis","volume":"22","author":"Rangan","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R103-23-20230601","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000166599","article-title":"Rapamycin attenuates the severity of murine adriamycin nephropathy","volume":"29","author":"Lui","year":"2009","journal-title":"Am J Nephrol"},{"key":"R104-23-20230601","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000020648","article-title":"Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative","volume":"8","author":"Daniel","year":"2000","journal-title":"Exp Nephrol"},{"key":"R105-23-20230601","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","article-title":"mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes","volume":"296","author":"Vollenbroker","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"R106-23-20230601","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfn574","article-title":"Sirolimus interacts with pathways essential for podocyte integrity","volume":"24","author":"Letavernier","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R107-23-20230601","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000103918","article-title":"Effects of rapamycin on active Heymann nephritis","volume":"27","author":"Naumovic","year":"2007","journal-title":"Am J Nephrol"},{"key":"R108-23-20230601","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1111\/j.1600-6143.2005.01120.x","article-title":"Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat","volume":"5","author":"Daniel","year":"2005","journal-title":"Am J Transplant"},{"key":"R109-23-20230601","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1159\/000116112","article-title":"The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat","volume":"108","author":"Wittmann","year":"2008","journal-title":"Nephron Exp Nephrol"},{"key":"R110-23-20230601","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R111-23-20230601","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/0961203307081401","article-title":"Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment","volume":"16","author":"Ramos-Barr\u00f3n","year":"2007","journal-title":"Lupus"},{"key":"R112-23-20230601","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1681\/ASN.2007121375","article-title":"Differential effects of rapamycin in anti-GBM glomerulonephritis","volume":"19","author":"Hochegger","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R113-23-20230601","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1681\/ASN.V84616","article-title":"Vascular expression of polycystin","volume":"8","author":"Griffin","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"R114-23-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.V1211","article-title":"Vascular expression of polycystin-2","volume":"12","author":"Torres","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R115-23-20230601","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1073\/pnas.94.12.6397","article-title":"Polycystin: In vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein","volume":"94","author":"Ibraghimov-Beskrovnaya","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R116-23-20230601","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1097\/01.ASN.0000080185.38113.A3","article-title":"Analysis of the polycystins in aortic vascular smooth muscle cells","volume":"14","author":"Qian","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R117-23-20230601","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00424-008-0561-y","article-title":"PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta","volume":"457","author":"Morel","year":"2009","journal-title":"Pflugers Arch"},{"key":"R118-23-20230601","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/CIRCULATIONAHA.107.692996","article-title":"Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation","volume":"116","author":"Raichlin","year":"2007","journal-title":"Circulation"},{"key":"R119-23-20230601","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCRESAHA.108.192765","article-title":"Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades","volume":"104","author":"Abou Alaiwi","year":"2009","journal-title":"Circ Res"},{"key":"R120-23-20230601","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1046\/j.1523-1755.2003.00236.x","article-title":"Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease","volume":"64","author":"Wang","year":"2003","journal-title":"Kidney Int"},{"key":"R121-23-20230601","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0022-5347(17)73123-0","article-title":"The arterial supply of the congenital polycystic kidney and its relation to the clinical picture","volume":"21","author":"Ritter","year":"1929","journal-title":"J Urol"},{"key":"R122-23-20230601","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199209243271303","article-title":"Intracranial aneurysms in autosomal dominant polycystic kidney disease","volume":"327","author":"Chapman","year":"1992","journal-title":"N Engl J Med"},{"key":"R123-23-20230601","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2215\/CJN.02330607","article-title":"Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: From impaired tubules to impaired carotid and coronary arteries","volume":"3","author":"Turkmen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R124-23-20230601","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/ki.1992.413","article-title":"Renal histology in polycystic kidney disease with incipient and advanced renal failure","volume":"42","author":"Zeier","year":"1992","journal-title":"Kidney Int"},{"key":"R125-23-20230601","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archinte.1931.00140210163013","article-title":"Hypertension in cases of polycystic kidney","volume":"47","author":"Schacht","year":"1931","journal-title":"Arch Intern Med"},{"key":"R126-23-20230601","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-5347(17)62101-3","article-title":"The importance of selective renal angiography in the diagnosis of polycystic disease","volume":"102","author":"Ettinger","year":"1969","journal-title":"J Urol"},{"key":"R127-23-20230601","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.ki.5001725","article-title":"Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: A corrosion cast study","volume":"70","author":"Wei","year":"2006","journal-title":"Kidney Int"},{"key":"R128-23-20230601","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1523-1755.2001.00768.x","article-title":"Angiogenesis in autosomal-dominant polycystic kidney disease","volume":"60","author":"Bello-Reuss","year":"2001","journal-title":"Kidney Int"},{"key":"R129-23-20230601","first-page":"45","article-title":"The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure","volume":"24","author":"Martinez-Lemus","year":"2009","journal-title":"Physiology (Bethesda"},{"key":"R130-23-20230601","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1096\/fj.01-0658com","article-title":"Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling","volume":"16","author":"Humar","year":"2002","journal-title":"FASEB J"},{"key":"R131-23-20230601","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5002550","article-title":"VEGF receptor inhibition slows the progression of polycystic kidney disease","volume":"72","author":"Tao","year":"2007","journal-title":"Kidney Int"},{"key":"R132-23-20230601","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1078-0432.CCR-06-2416","article-title":"Vascular endothelial growth factor and its relationship to inflammatory mediators","volume":"13","author":"Angelo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R134-23-20230601","doi-asserted-by":"crossref","first-page":"36112","DOI":"10.1074\/jbc.M703914200","article-title":"Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1\/phosphatidylinositol 3-kinase\/Akt2 feedback signaling","volume":"282","author":"Martin","year":"2007","journal-title":"J Biol Chem"},{"key":"R135-23-20230601","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4049\/jimmunol.180.4.2357","article-title":"HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway","volume":"180","author":"Jindra","year":"2008","journal-title":"J Immunol"},{"key":"R136-23-20230601","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000118462.22970.BE","article-title":"Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN","volume":"109","author":"Mourani","year":"2004","journal-title":"Circulation"},{"key":"R137-23-20230601","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.107.761932","article-title":"Suppression of c-Cbl tyrosine phosphorylation inhibits neointimal formation in balloon-injured rat arteries","volume":"118","author":"Tang","year":"2008","journal-title":"Circulation"},{"key":"R138-23-20230601","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/01.CIR.0000164271.01172.1A","article-title":"Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents","volume":"111","author":"Sousa","year":"2005","journal-title":"Circulation"},{"key":"R139-23-20230601","doi-asserted-by":"crossref","first-page":"889.e1","DOI":"10.1016\/j.ahj.2008.02.004","article-title":"Effect of rapamycin therapy on coronary artery physiology early after cardiac transplantation","volume":"155","author":"Sinha","year":"2008","journal-title":"Am Heart J"},{"key":"R140-23-20230601","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/cvr\/cvn024","article-title":"In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function","volume":"78","author":"Barilli","year":"2008","journal-title":"Cardiovasc Res"},{"key":"R141-23-20230601","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.bbrc.2008.05.154","article-title":"mTORC2 regulates PGE2-mediated endothelial cell survival and migration","volume":"372","author":"Dada","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"R142-23-20230601","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.RES.0000253094.03023.3f","article-title":"Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2","volume":"100","author":"Li","year":"2007","journal-title":"Circ Res"},{"key":"R143-23-20230601","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/ATVBAHA.109.185918","article-title":"Rapamycin inhibition of the Akt\/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase","volume":"29","author":"Xue","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R144-23-20230601","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.M700563200","article-title":"The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells","volume":"282","author":"Dormond","year":"2007","journal-title":"J Biol Chem"},{"key":"R145-23-20230601","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/21218","article-title":"Regulation of endothelium-derived nitric oxide production by the protein kinase Akt","volume":"399","author":"Fulton","year":"1999","journal-title":"Nature"},{"key":"R146-23-20230601","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1172\/JCI24726","article-title":"Akt1\/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis","volume":"115","author":"Ackah","year":"2005","journal-title":"J Clin Invest"},{"key":"R147-23-20230601","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7326\/0003-4819-146-3-200702060-00146","article-title":"Development of coronary aneurysm after drug-eluting stent implantation","volume":"146","author":"Bavry","year":"2007","journal-title":"Ann Intern Med"},{"key":"R148-23-20230601","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"R149-23-20230601","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1253\/circj.72.1201","article-title":"Very late stent thrombosis associated with multiple stent fractures and peri-stent aneurysm formation after sirolimus-eluting stent implantation","volume":"72","author":"Lee","year":"2008","journal-title":"Circ J"},{"key":"R150-23-20230601","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jacc.2005.11.092","article-title":"Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings","volume":"47","author":"Kotani","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R151-23-20230601","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"R152-23-20230601","doi-asserted-by":"crossref","first-page":"13544","DOI":"10.1073\/pnas.0800041105","article-title":"Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice","volume":"105","author":"Fujishita","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R153-23-20230601","doi-asserted-by":"crossref","first-page":"C419","DOI":"10.1152\/ajpcell.00038.2007","article-title":"VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25\/\u2212) mice","volume":"293","author":"Amura","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"R154-23-20230601","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.ki.5000314","article-title":"VEGF receptor 2 blockade leads to renal cyst formation in mice","volume":"69","author":"Grath-Morrow","year":"2006","journal-title":"Kidney Int"},{"key":"R155-23-20230601","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1681\/ASN.V1271448","article-title":"Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function","volume":"12","author":"Kang","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R156-23-20230601","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00041552-200301000-00008","article-title":"Vascular endothelial growth factor: A new player in the pathogenesis of renal fibrosis","volume":"12","author":"Kang","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R157-23-20230601","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ki.2008.350","article-title":"Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics","volume":"74","author":"Fine","year":"2008","journal-title":"Kidney Int"},{"key":"R158-23-20230601","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.transproceed.2009.02.005","article-title":"Hypertension induced by immunosuppressive drugs: A comparative analysis between sirolimus and cyclosporine","volume":"41","author":"Reis","year":"2009","journal-title":"Transplant Proc"},{"key":"R159-23-20230601","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: Update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am J Med"},{"key":"R160-23-20230601","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","article-title":"Use of sirolimus in solid organ transplantation","volume":"67","author":"Augustine","year":"2007","journal-title":"Drugs"},{"key":"R161-23-20230601","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: A review of its use in renal and cardiac transplantation","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"key":"R162-23-20230601","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0b013e3181a059a1","article-title":"Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus-based therapy without calcineurin inhibitors","volume":"87","author":"Flechner","year":"2009","journal-title":"Transplantation"},{"key":"R163-23-20230601","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R164-23-20230601","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"R165-23-20230601","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"R166-23-20230601","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"R167-23-20230601","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR\u2212\/\u2212 mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"key":"R168-23-20230601","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model","volume":"2","author":"Blum","year":"2002","journal-title":"Am J Transplant"},{"key":"R169-23-20230601","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/01.TP.0000074310.40484.94","article-title":"Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis","volume":"76","author":"Chueh","year":"2003","journal-title":"Transplantation"},{"key":"R170-23-20230601","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/01.tp.0000237101.58974.43","article-title":"Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence","volume":"82","author":"Mulay","year":"2006","journal-title":"Transplantation"},{"key":"R171-23-20230601","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/MOT.0b013e3283193bad","article-title":"Chronic allograft dysfunction: Can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?","volume":"13","author":"Wali","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"R172-23-20230601","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R173-23-20230601","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1093\/ndt\/gfl447","article-title":"Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction","volume":"21","author":"Ruiz","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R174-23-20230601","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1600-6143.2007.02142.x","article-title":"Development of proteinuria after switch to sirolimus based immunosuppression in long term cardiac transplant patients","volume":"8","author":"Aliabadi","year":"2008","journal-title":"Am J Transplant"},{"key":"R175-23-20230601","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.healun.2009.03.010","article-title":"Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease","volume":"28","author":"Stephany","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"R176-23-20230601","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.tp.0000240055.49572.07","article-title":"Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells","volume":"83","author":"Mreich","year":"2007","journal-title":"Transplantation"},{"key":"R177-23-20230601","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/01.tp.0000185200.17589.74","article-title":"Proteinuria following a switch from calcineurin inhibitors to sirolimus","volume":"80","author":"Letavernier","year":"2005","journal-title":"Transplantation"},{"key":"R178-23-20230601","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trre.2007.12.001","article-title":"mToR inhibitors-induced proteinuria: Mechanisms, significance, and management","volume":"22","author":"Letavernier","year":"2008","journal-title":"Transplant Rev (Orlando"},{"key":"R179-23-20230601","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.ki.5001792","article-title":"Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients","volume":"70","author":"van den Akker","year":"2006","journal-title":"Kidney Int"},{"key":"R180-23-20230601","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00007890-200407271-01242","article-title":"Preliminary results of a randomized trial comparing sirolimus (SRL) vs cyclosporine (CsA) in 150 transplant recipients receiving a cadaveric renal graft","volume":"78","author":"Lebranchu","year":"2004","journal-title":"Transplantation"},{"key":"R181-23-20230601","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.tp.0000228921.43200.f7","article-title":"Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation","volume":"82","author":"Stephany","year":"2006","journal-title":"Transplantation"},{"key":"R182-23-20230601","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"Buchler","year":"2007","journal-title":"Am J Transplant"},{"key":"R183-23-20230601","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/ndt\/gfm181","article-title":"Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols","volume":"22","author":"Diekmann","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R184-23-20230601","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1432-2277.2008.00811.x","article-title":"Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy","volume":"22","author":"Neau-Cransac","year":"2009","journal-title":"Transpl Int"},{"key":"R185-23-20230601","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R186-23-20230601","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/ndt\/gfh079","article-title":"Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies","volume":"19","author":"Fervenza","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R187-23-20230601","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00002018-200629120-00006","article-title":"Sirolimus-associated proteinuria and renal dysfunction","volume":"29","author":"Rangan","year":"2006","journal-title":"Drug Saf"},{"key":"R188-23-20230601","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2215\/CJN.00120605","article-title":"A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis","volume":"1","author":"Tumlin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R189-23-20230601","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/j.1600-6143.2005.01013.x","article-title":"Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing","volume":"5","author":"Senior","year":"2005","journal-title":"Am J Transplant"},{"key":"R190-23-20230601","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"R191-23-20230601","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1681\/ASN.V9101908","article-title":"Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease.","volume":"9","author":"Sharp","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R192-23-20230601","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0272-6386(00)70213-7","article-title":"Hypertension, proteinuria, and progression of autosomal dominant polycystic kidney disease: Where do we go from here?","volume":"35","author":"Torres","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R193-23-20230601","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1093\/ndt\/gfp280","article-title":"Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease","volume":"24","author":"Serra","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R194-23-20230601","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"R195-23-20230601","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"key":"R196-23-20230601","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1983.51","article-title":"Rate of functional deterioration in polycystic kidney disease","volume":"23","author":"Franz","year":"1983","journal-title":"Kidney Int"},{"key":"R197-23-20230601","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R198-23-20230601","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-8-13","article-title":"Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study","volume":"8","author":"Serra","year":"2007","journal-title":"BMC Nephrol"},{"key":"R199-23-20230601","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/ndt\/gfl246","article-title":"Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): Is there light at the end of the tunnel?","volume":"21","author":"Walz","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R200-23-20230601","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.transproceed.2009.05.032","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease: A pilot study","volume":"41","author":"Soliman","year":"2009","journal-title":"Transplant Proc"},{"key":"R201-23-20230601","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/TP.0b013e3181a05b7a","article-title":"Management of side effects of sirolimus therapy","volume":"87","author":"Stallone","year":"2009","journal-title":"Transplantation"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201007000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:44Z","timestamp":1786369184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201007000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":197,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01360210","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}